JOP20190072A1 - مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم - Google Patents
مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدمInfo
- Publication number
- JOP20190072A1 JOP20190072A1 JOP/2019/0072A JOP20190072A JOP20190072A1 JO P20190072 A1 JOP20190072 A1 JO P20190072A1 JO P20190072 A JOP20190072 A JO P20190072A JO P20190072 A1 JOP20190072 A1 JO P20190072A1
- Authority
- JO
- Jordan
- Prior art keywords
- compound
- synthase inhibitors
- hematopoietic prostaglandin
- azetidine derivatives
- substituted cyclobutane
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/93—Spiro compounds
- C07C2603/94—Spiro compounds containing "free" spiro atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407634P | 2016-10-13 | 2016-10-13 | |
PCT/IB2017/056320 WO2018069863A1 (en) | 2016-10-13 | 2017-10-12 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20190072A1 true JOP20190072A1 (ar) | 2019-04-07 |
Family
ID=60320926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0072A JOP20190072A1 (ar) | 2016-10-13 | 2017-06-16 | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
Country Status (24)
Country | Link |
---|---|
US (1) | US11053234B2 (ar) |
EP (1) | EP3526206A1 (ar) |
JP (1) | JP6938628B2 (ar) |
KR (1) | KR20190072565A (ar) |
CN (1) | CN110072857A (ar) |
AR (1) | AR109931A1 (ar) |
AU (1) | AU2017342156B2 (ar) |
BR (1) | BR112019007609A2 (ar) |
CA (1) | CA3038756A1 (ar) |
CL (1) | CL2019000986A1 (ar) |
CO (1) | CO2019003482A2 (ar) |
CR (1) | CR20190174A (ar) |
DO (1) | DOP2019000087A (ar) |
EA (1) | EA201990904A1 (ar) |
IL (1) | IL265597A (ar) |
JO (1) | JOP20190072A1 (ar) |
MA (1) | MA46531A (ar) |
MX (1) | MX2019004320A (ar) |
PE (1) | PE20191020A1 (ar) |
PH (1) | PH12019500811A1 (ar) |
TW (1) | TW201827412A (ar) |
UY (1) | UY37440A (ar) |
WO (1) | WO2018069863A1 (ar) |
ZA (1) | ZA201901848B (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
CN110753692A (zh) * | 2017-06-13 | 2020-02-04 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的化学化合物 |
CR20200054A (es) * | 2017-08-09 | 2020-03-21 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
WO2020168011A1 (en) | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
CN113582880B (zh) * | 2020-04-30 | 2023-11-17 | 南京药石科技股份有限公司 | 一种(3-氨基二环[1.1.1]戊烷-1-基)氨基甲酸叔丁酯的制备方法 |
CN111574473A (zh) * | 2020-06-04 | 2020-08-25 | 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) | 一种氨基噻唑类化合物的合成方法 |
CN111549000B (zh) * | 2020-06-18 | 2022-07-29 | 中国医学科学院整形外科医院 | 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用 |
CA3183214A1 (en) | 2020-06-19 | 2021-12-23 | Motoaki Baba | Condensed ring compounds that inhibit h-pgds |
CN114085167A (zh) * | 2021-12-13 | 2022-02-25 | 华中药业股份有限公司 | 一种杂质ts-3a的制备方法 |
WO2023201014A1 (en) * | 2022-04-15 | 2023-10-19 | Vanderbilt University | Benzothiazole-phenylsulfonyl-piperidine analogs as activators of n-acylphosphatidylethanolamine hydrolyzing phospholipase d |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4031221A (en) * | 1974-06-17 | 1977-06-21 | American Hoechst Corporation | Method of treating pain and hypertension |
FI87559C (fi) | 1985-02-28 | 1993-01-25 | Robins Co Inc A H | Foerfarande foer framstaellning av aktiva 3-fenyloxiazetidinkarboxamider |
US4956359A (en) | 1985-02-28 | 1990-09-11 | A. H. Robins Company, Inc. | 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics |
US6809088B2 (en) * | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
GB9801501D0 (en) | 1998-01-23 | 1998-03-18 | Cerebrus Ltd | Chemical compounds - II |
GB9917385D0 (en) | 1999-07-23 | 1999-09-22 | Cerebrus Ltd | Chemical compounds-I |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JP2007522233A (ja) * | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療におけるそれらの使用 |
WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
EP1742932A1 (en) * | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
GB0514017D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンd合成酵素を阻害するピリミジン化合物 |
PE20070589A1 (es) * | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
US20070208426A1 (en) * | 2006-03-03 | 2007-09-06 | Sdgi Holdings, Inc. | Spinal implant with improved surface properties for delivery |
EP1996545A1 (en) * | 2006-03-10 | 2008-12-03 | Boehringer Ingelheim International GmbH | Soluble epoxide hydrolase inhibitors and methods of using same |
US20110172230A1 (en) | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
KR20090125852A (ko) | 2007-03-30 | 2009-12-07 | 사노피-아벤티스 | Pgds 억제제로서의 피리미딘 하이드라지드 화합물 |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
PL2265578T3 (pl) * | 2008-03-04 | 2015-12-31 | Vernalis R&D Ltd | Pochodne azetydyny |
JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
CA2724998A1 (en) | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
WO2010024903A1 (en) * | 2008-08-29 | 2010-03-04 | Yangbo Feng | BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS |
CA2736955C (en) | 2008-09-22 | 2016-02-16 | Gregory W. Endres | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
ES2564454T3 (es) | 2009-03-09 | 2016-03-22 | Taiho Pharmaceutical Co., Ltd. | Compuesto de piperazina que puede inhibir la prostaglandina D sintasa |
US20120196854A1 (en) | 2009-10-06 | 2012-08-02 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition comprising aromatic heterocyclic compound |
NZ599099A (en) | 2009-10-08 | 2013-05-31 | Sanofi Sa | Phenyloxadiazole derivatives as pgds inhibitors |
AU2011208139B2 (en) | 2010-01-22 | 2014-10-23 | Taiho Pharmaceutical Co., Ltd. | Piperazine compound having a PGDS inhibitory effect |
US8952037B2 (en) | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
US8497265B2 (en) | 2010-05-13 | 2013-07-30 | Amgen Inc. | Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors |
US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
NZ608116A (en) * | 2010-09-13 | 2014-05-30 | Novartis Ag | Triazine-oxadiazoles |
KR101400192B1 (ko) | 2010-12-31 | 2014-05-27 | 제일모직 주식회사 | 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자 |
EP3354640A3 (en) * | 2011-04-13 | 2018-10-31 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
RU2013156864A (ru) | 2011-05-23 | 2015-06-27 | Санофи | Способ получения дейтерированных соединений, содержащих n-алкильные группы |
WO2013074387A1 (en) * | 2011-11-14 | 2013-05-23 | Merck Sharp & Dohme Corp. | Imidazole derivatives |
US9499533B2 (en) * | 2012-03-27 | 2016-11-22 | Shionogi & Co., Ltd. | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity |
TWI585088B (zh) * | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
CN106536518B (zh) | 2014-05-19 | 2020-05-12 | 勃林格殷格翰动物保健美国公司 | 驱蠕虫化合物 |
TWI695831B (zh) * | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
US10343992B2 (en) | 2015-03-30 | 2019-07-09 | Missions Therapeutics Limited | 1-cyano-pyrrolidine compounds as USP30 inhibitors |
KR20180095580A (ko) | 2015-12-17 | 2018-08-27 | 아스텍스 테라퓨틱스 리미티드 | H-pgds 억제제로서의 퀴놀린-3-카르복스아미드 |
JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
-
2017
- 2017-06-16 JO JOP/2019/0072A patent/JOP20190072A1/ar unknown
- 2017-10-11 TW TW106134668A patent/TW201827412A/zh unknown
- 2017-10-11 AR ARP170102843A patent/AR109931A1/es unknown
- 2017-10-11 UY UY0001037440A patent/UY37440A/es unknown
- 2017-10-12 EA EA201990904A patent/EA201990904A1/ru unknown
- 2017-10-12 CN CN201780075127.1A patent/CN110072857A/zh active Pending
- 2017-10-12 AU AU2017342156A patent/AU2017342156B2/en not_active Ceased
- 2017-10-12 PE PE2019000741A patent/PE20191020A1/es unknown
- 2017-10-12 EP EP17797738.6A patent/EP3526206A1/en not_active Withdrawn
- 2017-10-12 MX MX2019004320A patent/MX2019004320A/es unknown
- 2017-10-12 US US16/341,113 patent/US11053234B2/en active Active
- 2017-10-12 JP JP2019520150A patent/JP6938628B2/ja active Active
- 2017-10-12 MA MA046531A patent/MA46531A/fr unknown
- 2017-10-12 CR CR20190174A patent/CR20190174A/es unknown
- 2017-10-12 CA CA3038756A patent/CA3038756A1/en not_active Abandoned
- 2017-10-12 KR KR1020197013195A patent/KR20190072565A/ko not_active Application Discontinuation
- 2017-10-12 WO PCT/IB2017/056320 patent/WO2018069863A1/en unknown
- 2017-10-12 BR BR112019007609A patent/BR112019007609A2/pt not_active Application Discontinuation
-
2019
- 2019-03-25 IL IL265597A patent/IL265597A/en unknown
- 2019-03-26 ZA ZA2019/01848A patent/ZA201901848B/en unknown
- 2019-04-08 CO CONC2019/0003482A patent/CO2019003482A2/es unknown
- 2019-04-08 DO DO2019000087A patent/DOP2019000087A/es unknown
- 2019-04-11 CL CL2019000986A patent/CL2019000986A1/es unknown
- 2019-04-12 PH PH12019500811A patent/PH12019500811A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201990904A1 (ru) | 2019-08-30 |
TW201827412A (zh) | 2018-08-01 |
WO2018069863A1 (en) | 2018-04-19 |
MA46531A (fr) | 2019-08-21 |
BR112019007609A2 (pt) | 2019-07-02 |
AR109931A1 (es) | 2019-02-06 |
CR20190174A (es) | 2019-08-21 |
JP6938628B2 (ja) | 2021-09-22 |
JP2019536757A (ja) | 2019-12-19 |
US11053234B2 (en) | 2021-07-06 |
KR20190072565A (ko) | 2019-06-25 |
CN110072857A (zh) | 2019-07-30 |
MX2019004320A (es) | 2019-06-12 |
UY37440A (es) | 2018-04-30 |
CL2019000986A1 (es) | 2019-06-21 |
PH12019500811A1 (en) | 2020-01-20 |
CO2019003482A2 (es) | 2019-04-12 |
AU2017342156A1 (en) | 2019-04-18 |
IL265597A (en) | 2019-05-30 |
EP3526206A1 (en) | 2019-08-21 |
ZA201901848B (en) | 2021-01-27 |
CA3038756A1 (en) | 2018-04-19 |
DOP2019000087A (es) | 2019-06-16 |
AU2017342156B2 (en) | 2020-10-22 |
US20190241554A1 (en) | 2019-08-08 |
PE20191020A1 (es) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20190072A1 (ar) | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم | |
PH12017502331A1 (en) | 1,4-substituted piperidine derivatives | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
TN2016000581A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
JO3501B1 (ar) | مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام) | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
PH12015502192A1 (en) | Novel compounds | |
SG195319A1 (en) | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
PH12018502012A1 (en) | Griseofulvin compound | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
MX2023003264A (es) | Inhibidores de cdk y su uso como productos fármaceuticos. | |
MA39374A1 (fr) | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle | |
MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
TN2021000025A1 (en) | Novel heterocyclic amine derivative and pharmaceutical composition comprising same | |
BR112015027164A2 (pt) | novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso | |
BR112013027395A2 (pt) | inibidores de 17alfa-hidroxilase/c17,20-liase | |
IN2014MN02433A (ar) | ||
UY38455A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
BR112018000925A2 (pt) | composto heterocíclico contendo nitrogênio |